Thursday, November 14, 2024
HomeStock MarketCassava Sciences' Alzheimer's drug Simufilam is superior

Cassava Sciences’ Alzheimer’s drug Simufilam is superior


travelinglight/iStock through Getty Pictures

Cassava Science (NASDAQ: SAVA) introduced Wednesday that its lead candidate simufil slowed cognitive decline by 38% in comparison with a placebo in a small proof-of-concept research in sufferers with delicate to average Alzheimer’s illness.

The research, which is being carried out within the US, known as the Cognition Upkeep Research (CMS).



Supply hyperlink

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments